Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Expert Opin Ther Targets ; 28(5): 357-373, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38861226

RÉSUMÉ

INTRODUCTION: HIF-1α, a key player in medical science, holds immense significance in therapeutic approaches. This review delves into its complex dynamics, emphasizing the delicate balance required for its modulation. HIF-1α stands as a cornerstone in medical research, its role extending to therapeutic strategies. This review explores the intricate interplay surrounding HIF-1α, highlighting its critical involvement and the necessity for cautious modulation. AREAS COVERED: In sickle cell disease (SCD), HIF-1α's potential to augment fetal hemoglobin (HbF) production and mitigate symptoms is underscored. Furthermore, its role in cancer is examined, particularly its influence on survival in hypoxic tumor microenvironments, angiogenesis, and metastasis. The discussion extends to the intricate relationship between HIF-1α modulation and cancer risks in SCD patients, emphasizing the importance of balancing therapeutic benefits and potential hazards. EXPERT OPINION: Managing HIF-1α modulation in SCD patients requires a nuanced approach, considering therapeutic potential alongside associated risks, especially in exacerbating cancer risks. An evolutionary perspective adds depth, highlighting adaptations in populations adapted to low-oxygen environments and aligning cancer cell metabolism with primitive cells. The role of HIF-1α as a therapeutic target is discussed within the context of complex cancer biology and metabolism, acknowledging varied responses across diverse cancers influenced by intricate evolutionary adaptations.


Sujet(s)
Drépanocytose , Sous-unité alpha du facteur-1 induit par l'hypoxie , Thérapie moléculaire ciblée , Tumeurs , Microenvironnement tumoral , Humains , Drépanocytose/physiopathologie , Drépanocytose/traitement médicamenteux , Tumeurs/anatomopathologie , Tumeurs/traitement médicamenteux , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Animaux , Hémoglobine foetale/métabolisme , Néovascularisation pathologique
2.
ACS Chem Neurosci ; 13(8): 1263-1272, 2022 04 20.
Article de Anglais | MEDLINE | ID: mdl-35385250

RÉSUMÉ

Parkinson's disease (PD) is the second most common devastating neurodegenerative disorder. Presently used therapies for PD have severe side effects and are limited to only temporary improvement. Therefore, a new therapeutic approach to treat PD urgently needs to be developed. α-Lactalbumin, the most abundant milk protein in camel milk, has been attributed to various medicinal properties. This study intended to investigate the neuroprotective efficacy of the camel α-lactalbumin and oleic acid (CLOA) complex. One mechanism postulated to underlie neuroprotection by the CLOA complex is the induction of silent information regulatory protein (SIRT1). SIRT1 is known to be involved in several pathological and physiological processes, and it has been suggested that SIRT1 plays a protective role in PD. Oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis are involved in PD pathogenesis. Our results revealed that SIRT1 inhibits oxidative stress by maintaining HIF-1α in a deacetylated state. SIRT1 upregulates the expression of FOXO3a and HSF-1, thus inhibiting apoptosis and maintaining the homeostasis of cellular proteins. Increased SIRT1 expression reduces the levels of TNF-α, IL-6, and IL-8, which in turn inhibits neuroinflammation. In addition to SIRT1, the CLOA complex also enhances the expression of survivin and leptin and promotes the survival of neuroblastoma cells. Altogether, our results suggest that the CLOA complex might be a novel therapeutic molecule that could ameliorate neuronal cell damage in PD.


Sujet(s)
Neuroprotecteurs , Maladie de Parkinson , Animaux , Chameaux/métabolisme , Lactalbumine/métabolisme , Lactalbumine/pharmacologie , Lactalbumine/usage thérapeutique , Neuroprotection , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/usage thérapeutique , Acide oléique/pharmacologie , Acide oléique/usage thérapeutique , Stress oxydatif , Maladie de Parkinson/traitement médicamenteux , Roténone , Sirtuine-1/métabolisme , Sirtuine-1/pharmacologie , Sirtuine-1/usage thérapeutique
4.
Neurotox Res ; 39(4): 1123-1133, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-33740236

RÉSUMÉ

Genistein (GE), a plant-derived isoflavone, is a polyphenolic non-steroidal compound. Studies showed that GE possesses anti-cancer, anti-inflammatory, anti-microbial, anti-oxidant, and anti-apoptotic activities. However, the neuroprotective role of GE in amnesia has not been studied. This study aimed to evaluate the anti-amnesic potential of GE in a mice model of hypoxia-induced amnesia and to understand the underlying mechanism. Mice were exposed to hypoxia (10% O2) and administered vehicle or GE (10, 20, 30 mg/kg) orally for 28 days. Thereafter, Morris water maze (MWM), novel object recognition (NOR), and passive avoidance task (PAT) were performed to evaluate cognitive behavior. Next, we performed biochemical tests and gene expression analysis to uncover the mechanism underlying GE mode of action. Our results showed that GE-treatment ameliorated hypoxia-induced cognitive dysfunctions in mice. Further, GE-treatment suppressed the oxidative stress in the hippocampus of amnesic mice as evidenced by reduced lipid peroxidation, reduced nitrite and ROS levels, and increased levels of reduced glutathione (GSH) and increased total antioxidant capacity. GE treatment reduced the expression of pro-inflammatory cytokines TNFα, IL1ß, IL6, and MCP-1 and increased the expression of anti-inflammatory cytokine IL10 in the hippocampus of amnesic mice. Finally, GE treatment enhanced the expression of neuroprotective genes including BDNF, CREB, CBP, and IGF1 in the hippocampus of amnesic mice. Altogether, our results showed that GE treatment prevents hypoxia-induced cognitive dysfunction in mice by reducing oxidative stress and suppressing neuroinflammation while increasing the expression of neuroprotective genes in the hippocampus.


Sujet(s)
Dysfonctionnement cognitif/prévention et contrôle , Génistéine/usage thérapeutique , Hippocampe/effets des médicaments et des substances chimiques , Hypoxie/traitement médicamenteux , Neuroprotecteurs/usage thérapeutique , Stress oxydatif/effets des médicaments et des substances chimiques , Animaux , Apprentissage par évitement/effets des médicaments et des substances chimiques , Apprentissage par évitement/physiologie , Dysfonctionnement cognitif/étiologie , Dysfonctionnement cognitif/métabolisme , Relation dose-effet des médicaments , Génistéine/pharmacologie , Hippocampe/métabolisme , Hypoxie/complications , Hypoxie/métabolisme , Inflammation/métabolisme , Inflammation/prévention et contrôle , Mâle , Souris , Neuroprotecteurs/pharmacologie , Stress oxydatif/physiologie , Phyto-oestrogènes/pharmacologie , Phyto-oestrogènes/usage thérapeutique
5.
ACS Chem Neurosci ; 11(24): 4416-4425, 2020 12 16.
Article de Anglais | MEDLINE | ID: mdl-33253528

RÉSUMÉ

Parkinson's Disease (PD) is characterized by increased oxidative stress and decreased level of dopamine. At present, the therapeutic interventions of PD are associated with undesirable adverse effects. To overcome these side effects, a new candidate bioinspired molecule is needed for the management of PD. Camel α-lactalbumin (α-LA) is the most abundant protein in camel's milk and has a potential to act as a nutraceutical supplement for neurological functions. Oleic acid, a monounsaturated fatty acid, has been widely associated with a reduced risk of PD. The present study aimed to formulate the camel α-LA and oleic acid (CLOA) complex under specific conditions and to evaluate its efficacy as a neuroprotective in rotenone induced PC12 cell model of PD. Our results demonstrated that removal of Ca++ ions from camel α-LA by EDTA enhances its binding efficiency with oleic acid, and the complex was characterized by UV-CD, ANS fluorescence spectroscopy, and NMR spectroscopy. Moreover, CLOA complex treatment reduced the oxidative stress and increased the cell viability by enhancing the level of dopamine and the expression of SIRT1, FOXO3a, HIF-1α, and HSF-1. We also validated the neuroprotective role of the complex by incubating the cells with CLOA complex prior to rotenone treatment. We inferred from the outcome of the results that the individual entity, i.e., α-LA or OA, is not as effective as the complex. Taken together, our study indicates that CLOA complex might be a potential candidate for the development of future therapeutic drugs for PD.


Sujet(s)
Lactalbumine , Maladie de Parkinson , Animaux , Chameaux , Lactalbumine/pharmacologie , Acide oléique/pharmacologie , Sirtuine-1
6.
Inflammation ; 43(5): 1589-1598, 2020 Oct.
Article de Anglais | MEDLINE | ID: mdl-32410071

RÉSUMÉ

Silent information regulator 1 (SIRT1) is a ubiquitously expressed protein and has an intricate role in the pathology, progression, and treatment of several diseases. SIRT1 is a NAD+-dependent deacetylase and regulates gene expression by histone deacetylation. Deletion of SIRT1 in the liver, pancreas, and brain significantly increases the reactive oxygen species (ROS) and inflammatory response. Literature survey on SIRT1 shows the evidence for its role in preventing oxidative stress and inflammation. Oxidative stress and inflammation are closely related pathophysiological processes and are involved in the pathogenesis of a number of chronic disorders such as fatty liver diseases, diabetes, and neurodegenerative diseases. Both oxidative stress and inflammation alter the expression of several genes such as nuclear factor E2 related factor (Nrf2), nuclear factor E2 related factor 2 (Nef2), nuclear factor kappa B (NF-kB), pancreatic and duodenal homeobox factor 1 (PDX1), interleukin-1 (IL1), forkhead box class O (FOXO), and tumour necrosis factor alpha (TNF-α). By annotating this knowledge, we can conclude that modulating the expression of SIRT1 might prevent the onset of diseases inexorably linked to the liver, pancreas, and brain. Graphical Abstract Role of silent information regulator 1 (SIRT1) in the pancreas, brain, and liver.


Sujet(s)
Médiateurs de l'inflammation/métabolisme , Stress oxydatif/physiologie , Espèces réactives de l'oxygène/métabolisme , Sirtuine-1/physiologie , Animaux , Encéphale/métabolisme , Encéphale/anatomopathologie , Humains , Inflammation/métabolisme , Inflammation/anatomopathologie , Foie/métabolisme , Foie/anatomopathologie , Pancréas/métabolisme , Pancréas/anatomopathologie , Transduction du signal/physiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE